Citywire for Financial Professionals

Worldwide Healthcare (Ordinary Share) WWH

Sector Specialist: Biotechnology/Life Sciences

Register or Sign in to receive email alerts for items in your favourites whenever we write about them

Add to Virtual Portfolio | Print page

Estimated NAV

2481.00

Share Price

2521.00

Total Returns on £1000 over 

Fund / Benchmark Total returns(%)
Worldwide Healthcare (Ordinary Share) Price 57.62%
Worldwide Healthcare (Ordinary Share) NAV 50.54%
FTSE World 51.43%
Total Returns on £1000

Discount / Premium Movement

Discount / Premium Movement

Shares

Share Type Yesterday's
Closing Price
Discount / Premium Diluted NAV Gearing Dividend
Est Last
Ordinary Share 2514.0 1.3% 2481.00 2456.00
15 Nov
112% 0.89%

Discrete performance % over

Fund / BenchmarkDec '14
Nov '15
Dec '15
Nov '16
Dec '16
Nov '17
Worldwide Healthcare (Ordinary Share) Price9.3520.0520.07
Worldwide Healthcare (Ordinary Share) NAV12.6714.9916.20
FTSE World1.2828.4116.44

Discrete performance over

Discrete Performance

Top 10 Holdings

Wright Medical Group, Inc. 4.34%
Alexion Pharmaceuticals, Inc. 3.75%
Novo-Nordisk 3.45%
Boston Scientific, Inc. 3.35%
Eli Lilly & Co. 3.06%
Merck & Co. Inc. 2.96%
Intuitive Surgical, Inc. 2.96%
Regeneron Pharmaceuticals, Inc. 2.76%
Incyte Corporation 2.56%
Nippon Shinyaku Co Ltd 2.27%

Sectors weighting

Pharmaceuticals 101.40%
Net Current Assets -1.40%

Regional weighting

North America Region 67.00%
Europe Developed ex-UK 16.00%
Japan 8.00%
Asia exc Japan 7.00%
Other Countries 1.00%
Cash/Cash Equivalent 1.00%
UK 0.00%
  • Investment trust info:

  • Sector Sector Specialist: Biotechnology/Life Sciences
  • Launch Date 28 Apr 1995
  • Currency GBX
  • Domicile UK
  • Share Price 2521.00
  • Share Type Ordinary Share
  • TIDM WWH
  • ISIN GB0003385308
  • Shares Issued (M) 48
  • Market Capital (£M) 1216.88
  • Gross Assets (£M) 1341.11
  • Net Assets (£M) 1200.94
  • TER (%) 0.90
  • Historic Dividend Yield (%) 0.89
  • Last AGM 21 Sep 2017
  • Next AGM 21 Sep 2018
  • Last Annual Report Date 14 Jul 2017
  • Next due Report Date 30 Sep 2017
  • Next due Report Type I/R
  • Objective:

  • To achieve a high level of capital growth by investing worldwide in a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities in the healthcare sector.
  • Management Group(s):

  • Close Finsbury Asset Management Ltd
  • Frostrow Capital LLP
  • OrbiMed Capital LLC
  • OrbiMed Capital LLC
  • Managed by:

  • Samuel Isaly Start: 28 Apr 1995
  • Sven Borho Start: 01 Feb 2013
  • Trevor M. Polischuk Start: 31 Mar 2015
  • Management Contract & Fees:

    OrbiMed, the Investment Manager, receives a periodic fee equal to 0.65% p.a. of the Company's net asset value. The Investment Management Agreement may be terminated by either party giving notice of not less than 12 months. Frostrow, the Administrator, receives a periodic fee equal to 0.30% p.a. of the Company's market capitalisation up to £150m, 0.20% p.a. of the market capitalisation in excess of £ 150m and up to £500m, and 0.125% p.a. of the market capitalisation in excess of £500m, plus a fixed amount equal to £ 57,500 p.a. Dependent on the level of long-term outperformance of the Company, the Investment Manager and the Administrator are entitled to the payment of a performance fee. The performance fee amounts to 16.5% of any outperformance of the NAV over the benchmark index, the Investment Manager receiving 15% and the Administrator receiving 1.5% respectively.

Sorry, this link is not
quite ready yet